FDA sets meeting to discuss improving benefit-risk assessments

FDA will seek input at a May 16 public hearing on ways to make benefit-risk assessments publicly accessible, which may include publishing benefit-risk

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE